Sygnature Discovery appoints Rick Davies to spearhead growth as Director of its UK Protein Sciences and Structural Biology business (formerly, Peak Proteins)
Sygnature Discovery is delighted to announce the appointment of Rick Davies as Director of Protein Sciences and Structural Biology in the UK.
The role will be instrumental in growing the protein science and structural biology offering and contributing to the growth of the business through scientific input and strategic direction. A key focus is to identify business opportunities as part of integrated Sygnature projects and to directly enable client objectives.
Rick brings extensive experience as a protein biochemist in big pharma, working across all major therapeutic areas. He has led teams in expressing and purifying protein targets for use in hundreds of drug discovery projects. Additionally, he provided leadership on the successful technology transfer and implementation of DNA-encoded library screening at AstraZeneca, while playing a key role in building a targeted degradation platform.
Rick will leverage his extensive drug discovery experience to contribute to individual Sygnature projects, while building on the excellent reputation for quality delivery from the UK Protein Science and Structural Biology department.
Commenting on his appointment Rick said, “I’m excited to join Sygnature Discovery and the Protein Science and Structural Biology team. I look forward to being able to apply my drug discovery knowledge to an even wider range of projects.”
“I’m delighted to welcome Rick Davies to Sygnature,” said David Witty, Chief Scientific Officer at Sygnature Discovery.
“Rick is an internationally recognised leader in protein science and drug discovery, with a distinguished track record of success from his time at AstraZeneca. His expertise and leadership will play a pivotal role in driving the continued development and growth of this area. Sygnature has built an outstanding reputation in this field, thanks to the exceptional work of our scientific team and the dedicated leadership of retiring director Mark Abbott.”
About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global biotech, pharma and NFP organizations. Since 2011, Sygnature Discovery has delivered 50 novel pre-clinical and 30 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.